MAIA Biotechnology
MAIAMAIA Biotechnology is a clinical-stage biopharmaceutical company focused on developing targeted immunotherapies for cancer.
Earnings
Next report
Nov 6, 2026 (In 4 days)Competitors
By market cap
By revenue growth
Profile
MAIA Biotechnology is a clinical-stage biopharmaceutical company focused on developing targeted immunotherapies for cancer. The company's core value proposition lies in its first-in-class telomere-targeting agents that utilize telomerase to induce cancer-specific cell death and activate the immune system. By sequencing these agents with existing checkpoint inhibitors, MAIA aims to overcome drug resistance and transform immunologically cold tumors into hot tumors responsive to therapy.
MAIA is a pioneer in telomere-targeting therapy, positioning its lead candidate ateganosine as a foundational priming treatment for the multi-billion dollar checkpoint inhibitor market.
FAQ
- What is MAIA Biotechnology's market cap?
- MAIA Biotechnology (MAIA) has a market capitalization of $72.9M and trades on AMEX.
- Who are MAIA Biotechnology's competitors?
- MAIA Biotechnology's key competitors include Geron Corporation, Bristol-Myers Squibb, Merck & Co., and others. These companies compete in similar markets and product categories.
- Who does MAIA Biotechnology partner with?
- MAIA Biotechnology's notable partners include Regeneron Pharmaceuticals, Inc., BeOne Medicines, Roche, and others.
- What subsidiaries does MAIA Biotechnology have?
- MAIA Biotechnology's subsidiaries include MAIA Biotechnology Australia Pty Ltd., MAIA Biotechnology Romania S.R.L., THIO Therapeutics, Inc..
- Where is MAIA Biotechnology headquartered?
- MAIA Biotechnology is headquartered in United States of America and employs approximately 13 people. It has been publicly traded since 2022.